Menu
- Home
+ - Publications
+
- Archives
+
- BCIQ
+
- Conferences
+
- eLearning
+
- Follow Us
Latest News
4:55 PM Nov 16, 2018
Tesaro stock rebounds on takeout report
Tesaro Inc. (NASDAQ:TSRO) declined to comment on a report of a potential sale that drove the company's...
4:55 PM Nov 16, 2018
Centrexion steps back from IPO amid volatile market
A decision by pain company Centrexion Therapeutics Corp. (Boston, Mass.) to not move forward with its...
4:18 PM Nov 16, 2018
Spotlight co-founder uses CRISPR screen to ID T cell regulator genes for cancer
Spotlight Therapeutics Inc. (Hayward, Calif.) co-founder Alexander Marson and colleagues at University of...
4:10 PM Nov 16, 2018
Adcetris gets speedy label expansion under FDA real-time pilot
FDA approved a label expansion for Adcetris brentuximab vedotin less than two weeks after Seattle Genetics...
4:06 PM Nov 16, 2018
Novartis joins call asking FDA to stop biosimilar trash-talkers
Novartis AG (NYSE:NVS; SIX:NOVN) joined Pfizer Inc. (NYSE:PFE) in asking FDA to stop campaigns from...
4:03 PM Nov 16, 2018
Postmarketing study delays increase, but Gottlieb hopeful on progress
Despite a slight slip in numbers for on-schedule postmarketing studies, FDA Commissioner Scott Gottlieb...
3:22 PM Nov 16, 2018
Alphamab Oncology raises more than $100M series A
Immuno-oncology company Alphamab Oncology (Suzhou, China) raised over $100 million in a series A round to...
3:19 PM Nov 16, 2018
As Finance chair, Grassley will become gatekeeper of biopharma bills
Sen. Chuck Grassley (R-Iowa) said he will opt to serve as chairman of the Senate Finance Committee for the...
2:54 PM Nov 16, 2018
Pfizer to increase list price of 41 drugs
Pfizer Inc. (NYSE:PFE) said it plans to increase the list price for 41 medicines, effective Jan. 15. Last...
2:19 PM Nov 16, 2018
CHMP backs first all-oral sleeping sickness treatment, extensions for Blincyto, Opdivo-Yervoy combo
EMA's CHMP recommended a basket of approvals and label extensions on Friday, including the first all-oral...
1:52 PM Nov 16, 2018
Chi-Med down on fruquintinib OS miss in third-line NSCLC
Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said third-line treatment with fruquintinib missed the...
12:42 PM Nov 16, 2018
Imfinzi fails again in MYSTIC trial for first-line NSCLC
In another strike against tremelimumab, AstraZeneca plc (LSE:AZN; NYSE:AZN) said the anti-CTLA-4 mAb in...
5:23 AM Nov 16, 2018
Preventing DNA repair blocks inflammation
In Science, researchers at Karolinska Institute and colleagues reported a new approach to treat...
4:26 PM Nov 15, 2018
Arena licenses ralinepag to United, moves S1PR1 agonist to center stage
United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial...
4:14 PM Nov 15, 2018
Patients: Trust and transparency key to using social media, apps to gather data
Members of an FDA committee agreed that social media and digital technologies could help companies and the...
4:13 PM Nov 15, 2018
V-Bio, Gimv lead €37M Camel-IDS series A
Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million)...
4:10 PM Nov 15, 2018
U.K. biopharma stocks weather the Brexit storm
U.K. biopharma stocks held steady Thursday despite the turmoil caused by Brexit negotiations, while the...
4:01 PM Nov 15, 2018
NICE backs Novartis' Kymriah in acute lymphoblastic leukemia
U.K.'s NICE recommended in final guidance CAR T therapy Kymriah tisagenlecleucel from Novartis AG (NYSE:...
3:59 PM Nov 15, 2018
Cell-free DNA could identify likely Rubraca responders
Cell-free DNA analysis of BRCA reversion mutations could go beyond tissue-based diagnostics to help...
3:23 PM Nov 15, 2018
Boehringer, Epizyme to develop small molecules against epigenetic cancer targets
Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with Epizyme Inc. (NASDAQ:EPZM) to develop small...
About Biocentury
Contact
Support
Products & Solutions
Legal
- Follow Us
What is BioCentury?
BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.